4.
ES-SCLC生存期的单因素分析
Single analysis for survival of ES-SCLC
| Factor | n | MST (mo) | Range (mo) | P |
| *: OS of patients who did not receive local treatment of metastases compared with single-site, multi-site local treatment were statistically different (P < 0.01). **: OS of patients who received initiative local treatment of metastases compared with passive, none-local treatment of metastases were statistically different (P < 0.01). | ||||
| Total | 275 | 10.4 | 1.0-43.6 | |
| Gender | 0.328 | |||
| Male | 212 | 10.3 | 1.0-43.1 | |
| Female | 63 | 11.7 | 4.1-43.6 | |
| Age (yr) | 0.400 | |||
| < 65 | 176 | 10.5 | 2.3-43.1 | |
| ≥65 | 99 | 10.4 | 1.0-43.6 | |
| ECOG before treatment | 0.520 | |||
| 0 | 15 | 8.3 | 4.2-21.6 | |
| 1 | 222 | 10.5 | 1.0-43.6 | |
| 2 | 33 | 10.6 | 2.3-33.0 | |
| 3 | 5 | 7.2 | 1.2-27.0 | |
| Thoracic radiotherapy | < 0.001 | |||
| Yes | 122 | 14.3 | 3.1-43.6 | |
| No | 153 | 8.2 | 1.0-34.1 | |
| Prophylactic cranial irradiation | < 0.001 | |||
| Yes | 34 | 19.8 | 9.2-43.1 | |
| No | 241 | 9.9 | 1.0-43.6 | |
| Metastasis local treatment site | < 0.001* | |||
| Single | 85 | 12.3 | 2.8-34.1 | |
| Mutiple | 24 | 18.7 | 6.0-43.6 | |
| None | 166 | 8.9 | 1.0-28.8 | |
| Metastasis local treatment timing | 0.001** | |||
| Initiative | 66 | 16.0 | 2.8-43.6 | |
| Passive | 43 | 10.9 | 4.4-30.3 | |
| None | 166 | 9.4 | 1.0-28.8 | |
| Chemotherapy scheme | 0.854 | |||
| EP or EC | 219 | 10.9 | 1.0-43.6 | |
| Not EP or EC | 56 | 10.3 | 4.1-30.3 | |